« Return to News | Awards & Advancement

McGoldrick Leaves DIA, Brassington Named Acting Executive Director

Wednesday, August 6, 2008 08:01 AM

Linda McGoldrick, appointed executive director of the Drug Information Association (DIA) earlier this year, has left her position, according to a release on the DIA’s web site.

In her place, the DIA appointed William Brassington as acting executive director on an interim basis. The statement didn’t disclose why McGoldrick left.

According to the statement from Marie Dray, president DIA’s Board of Directors, Brassington has a long history of service with DIA. Since August 2003, he has been chief financial officer, and he served as acting executive director before McGoldrick was hired.

“Through these roles, William has gained the respect and confidence of the DIA staff, the Board of Directors and association members, enabling him to ensure seamless operations during this transition period,” Dray said in the statement.

The 18,000-member association provides a global exchange of drug information, and conducts education and training programs. In June, DIA hosted its most successful annual meeting in Boston with almost 9,000 members and speakers in attendance. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.